We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




An Experimental Analgesic Is More Potent Than Morphine

By HospiMedica International staff writers
Posted on 10 Jan 2011
A new study describes morphine-6-0-sulfate, which although having a similar chemical structure to standard morphine, is potentially more potent, longer lasting, and less likely to cause constipation than standard morphine.

Researchers at Loyola University (Chicago, IL, USA) and the University of Kentucky (Lexington, USA) characterized the relatively little-known morphine derivative using a range of well-established rodent pain models, demonstrating that morphine-6-O-sulfate was efficacious using several routes of administration, including neuroaxial (injected into the intrathecal space), parenteral (injection into the peritoneum), and oral administration. More...
The drug showed potent, dose-related, analgesic activities against acute nociceptive pain (using the tail flick test), neuropathic pain (under chronic constriction nerve injury hyperalgesia and allodynia), and inflammatory pain (using the formalin test).

Morphine-6-0-sulfate maintained its maximum effect for three hours, compared with one-and-a-half hours for standard morphine. It also took the rats 25 days to build tolerance to morphine-6-0-sulfate, compared with 10 days with standard morphine. Morphine-6-0-sulfate was also more potent than standard morphine for neuropathic and inflammatory pain. The researchers did find that morphine-6-0-sulfate could cause constipation, but only at doses 10 to 20 times higher than the effective doses. Morphine-6-0-sulfate also had a good separation based on dose (at least 10-fold) between side effects and analgesia in all models of pain tested. In addition, morphine-6-O-sulfate had a more favorable potency ratio for delay of gastrointestinal transit and analgesia, when compared to morphine. The study was published in the December 2010 issue of the European Journal of Pharmacology.

"These preclinical findings suggest that morphine-6-O-sulfate is a potential candidate for development as a novel opioid for management of nociceptive, neuropathic, and mixed pain states,” said lead author Joseph Holtman, MD, PhD, and colleagues of the departments of anesthesiology and molecular pharmacology and therapeutics.

Related Links:
Loyola University
University of Kentucky



Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Hemostatic Agent
HEMOBLAST Bellows
Mobile X-Ray System
K4W
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.